Home World News Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients... World News Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 MAP Congress 2020: Molecular Analysis for Precision Oncology October 2, 2020 ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 How to Clean Your Home When Caring for Someone With Cancer October 7, 2020 Load more HOT NEWS Delivering Palliative Care by Telehealth Meets the Needs of People with... Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... PET Positivity After Two Cycles of ABVD Is Associated with a...
